Interchangeability of glibenclamide-containing drugs
Abstract
The article analyses the problem of interchangeability of glibenclamide-containing drugs that sometimes lack therapeutic equivalence even though their bioequivalence has been proven. The authors formulated the key factors affecting interchangeability of glibenclamide drugs and highlighted conditions that compromise interchangeability. Special attention was given to clinical pharmacology of glibenclamide and adverse reactions associated with sulfonylurea products. The article offers a summary of the main groups of glibenclamide drugs. It also substantiates the need for better coordination of production and clinical use of glibenclamide drugs which will help to ensure the comparability of generic and reference glibenclamide drugs in the long run.
About the Authors
G. I. Gorodetskaya
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. V. Shikh
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. V. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
S. Yu. Serebrova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. A. Sokova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
O. V. Muslimova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
T. V. Aleksandrova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
I. A. Mazerkina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
S. G. Rudnev
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Scientific substantiation, development and improvement of methodology for assessment of medicinal products interchangeability. Research report (intermediate). FSBI «SCEEMP» of the Ministry of Health of Russia; advisors: Romanov BK, Prokofiev AB, Yagudina RI; prepared by: Alyautdin RN, Zhuravleva MV. Moscow; 2015. 274 p. No. SR 115111740009. Deposited in CITIS on 16.02.2016, No. IKRBS 216021650027 (in Russian).
2. Mashkovsky MD. Medicines. V. 1. Moscow: Meditsina; 1984 (in Russian).
3. Dedov II, Shestakova MV, Mayorov AYu, Vikulova OK, Galstyan GR, Kuraeva TL, et al. Standards of specialized diabetes care. Diabetes mellitus 2017; 20(1S): 1–112 (in Russian).
4. Kukes VG, Sychev DA, Andreev DA, Arkhipov VV, Batischeva GA, Berdnikova NG, et al. Ñlinical pharmacology. 5th ed. Moscow: GEOTAR-Media; 2015 (in Russian).
5. Robertson RP, Porte D. The glucose receptor a defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin. Invest. 1973; 52(4): 870–6.
6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595–1607.
7. Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, Velho G, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest. 1993; 92(5): 2092–8.
8. Shestakova MV. Actual clinical practice of treatment of diabetes type 2 in the Russian Federation according to the prospective open observational program «DIA- CONTROL». Diabetes Mellitus 2011; (4): 75–80 (in Russian).
9. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in helht and disease. Diabetologia 1999; 42(8): 903–19.
10. Nedosugova LV, Balabolkin MI. Algorithm treatment diabetes type 2 diabetes. Moscow: MedExpertPress; 2008 (in Russian).
11. Muller G, Hartz D, Punter J, Okonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta–cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994; 1191(2): 267–77.
12. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002; 25(8): 1271–6.
13. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first- and second-phase â-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989; 38(8): 767–72.
14. Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 2009; 40(5): 387–92.
15. Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009; 41(5): 387–90.
16. Balabolkin MI, Kreminskaya VM, Klebanova EM. Modern tactics of treatment of diabetes mellitus type 2. Consilium medicum 2001; 3(11): 535–40 (in Russian).
17. Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin- dependent diabetes mellitus after glyburide therapy. Metab Clin Exp. 1990; 39(3): 1204–10.
18. De Fronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984; 7(1): 72–80.
19. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evolution of glimepiride and glibenclamide. Eur Heart J. 1999; 20(6): 439–46.
20. Bartsch SE, Abberger T, Griesser UJ. Melt granulation of solid dispersions—granulation mechanism, tableting and dissolution behavior. Abstr. 17th Congress of the Austrian Pharmaceutical Society. Graz, 24–26 April, 2003.
21. Wei H, Lobenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci. 2006; 29(1): 45–52.
22. Karpov OI. Micronized glibenclamide—a modification of the dosage form and kinetics aimed at the result. Russian medical journal 2006; (26): 1940–3 (in Russian).
23. Glyburide Micronized Description. Available from: https://www.drugs.com/pro/glyburide-micronized.html.
24. Christ OE, Heptner W, Rupp W. Investigations on absorption, excretion and metabolism in man after administration of 14C-labelled HB 419. Horm Metab Res. 1969; 1 (Suppl. l): 51–4.
25. Gorodetsky VV, Gorodetskaya GI, Shikh EV, Zhukovskaya AV. Can we cause a drug induction of izoenzymes of cytochrome P450, metabolizing sulfonylureas in patients with type 2 diabetes mellitus with polymorphism of genes, encoding these izoensymes? Medicines and rational pharmacotherapy 2013; (2): 20–6 (in Russian). Available from: http://macff.ru/images/arhiv/2013-2.pdf.
26. Surendiran A, Pradhan SC, Agraval A, Subrahmanyam DK, Rajan S, Anichavezhi D, et al. Influence of CYP2C9 gene polymorphism on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol. 2011; 67(8): 797–801.
27. Rudakova IP, Ilyina IG, Skachilova SYa, Melentieva TA, Mikhalev OV, Samylina IA. Polymorphism and properties of drugs. Pharmacy 2009; (8): 42–4 (in Russian).
28. Zilov AV, Morgunova TB, Terekhova AL. The frequency of hypoglycemia and cardiovascular disorders in patients treated with sulfonylureas compared with other secretagogues: a systematic review. Diabetes Mellitus 2010; (2): 85–90 (in Russian).
29. Carlson RF, Isley WL, Ogrinc FG, Klobucar TR. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin- dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther. 1993; 15(5): 788–96.
30. State register of medicines. Available from: https://grls.rosminzdrav.ru (in Russian).
31. Antsiferov MB, Mayorov AYu. Use of combined oral glucose reducing drug Glibomet in the treatment of patients with type 2 diabetes mellitus. Moscow: Berlin-Chemie/Menarini Group; 2001 (in Russian).
32. Ametov AS. Diabetes mellitus type 2. Problems and solutions. Moscow: GEOTAR-Media; 2012 (in Russian).
33. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet. 2002; 41(15): 1301–9.
34. Nikonova TB. Modern algorithm for the treatment of type 2 diabetes mellitus. To whom and how to prescribe combined hypoglycemic preparations. Consilium medicum 2008; 10(9): 25–9 (in Russian).
35. Eadala P, Waud JP, Matthews SB, Green JT, Campell AK. Quantifying the «hidden» lactose in drugs used for the treatment of gastrointestinal conditions. Aliment Pharmacol Ther. 2009; 29(6): 677–87.
36. Trofimov SV. High molecular cellulose esters. Mechanism of action in sustained release matrix tablets. Dissolution profile of active drug depending on molecular weight and hydrophilic properties of polymers. Pharmacy & Pharmacology 2015; 3(5): 18–25 (in Russian).
37. Mogilyuk V. Lubricants for solid dosage forms: Compritol 888 ATO and Precirol ATO 5. Pharmaceutical industry 2010; (6): 60–3 (in Russian).
38. Suleiman MS, Najib NM. Isolation and physicochemical characterization of solid forms of glibenclamide. Int J Pharm.1989; 50(2): 103–9.
39. Yalkowsky SH, He Y. Handbook of aqueous solubility data. New York: CRC Press; 2003.
40. Trofimov SV, Stepanova EF. Medicinal forms of glibenclamide: modern technologies for an actual problems’ solution. Development and registration of medicines 2014; (7): 64–7 (in Russian).
41. Approved Drug Products with Therapeutic Equivalence Evaluations. 37th edition. 2017. Available from: https://goo.gl/LAUEC2.
42. Romanov BK, Sakaeva IV, Bunyatyan ND, Vasiliev AN, Bondarev VP, Prokofiev AB, et al. The algorithm of evaluation of interchangeability of pharmaceuticals. Medical Journal of the Russian Federation 2015; (5): 43–6 (in Russian).
43. Bukatina TM, Kazakov AS, Velts NYu, Darmostukova MA, Zatolochina KE, Alyautdin RN, et al. Ketoacidosis as unexpected adverse reaction SGLT2 inhibitor. Safety and Risk of Pharmacotherapy 2016; (4): 22–5 (in Russian).
44. Chuchalin AG, Hohlov AL, eds. Federal guidance on the use of drugs (formulary system). Issue XVIII. Moscow: Vidoks; 2017 (in Russian).
45. Scientific substantiation, development and improvement of methodology for assessment of medicinal products interchangeability. Research report (intermediate). FSBI «SCEEMP» of the Ministry of Health of Russia; advisors: Romanov BK, Prokofiev AB, Yagudina RI; prepared by: Alyautdin RN, Zhuravleva MV. Moscow; 2016. 365 p. No. SR 115111740009. Deposited in CITIS on 26.01.2017, No. IKRBS 217012640056-0 (in Russian).
Review
For citations:
Gorodetskaya G.I., Shikh E.V., Zhuravleva M.V., Serebrova S.Yu., Sokova E.A., Muslimova O.V., Aleksandrova T.V., Mazerkina I.A., Rudnev S.G. Interchangeability of glibenclamide-containing drugs. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(4):199-211. (In Russ.)
Views:
795
Email this article 